44 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
by medical/healthcare institutes, guideline bodies and other third-party organizations;
our expectations regarding the size of the patient populations
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
for Healthcare Providers, Fact Sheet for Patients and Parents/Caregivers and FDA Letter of Authorization on the GOHIBIC website (www.GOHIBIC.com).
Important … , pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash.
Healthcare providers and/or their designee are responsible
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
-19 patients and U.S. hospitals and related treatment recommendations by medical/healthcare institutes and other third-party organizations, our ability
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
treatment recommendations by medical/healthcare institutes and other third-party organizations, our ability to successfully commercialize
6-K
EX-99.1
IFRX
InflaRx N.V.
21 May 24
Report of Foreign Private Issuer
4:15pm
for Healthcare Providers, Fact Sheet for Patients and Parents/Caregivers and FDA Letter of Authorization on the GOHIBIC (vilobelimab) website (www.GOHIBIC.com … , supraventricular tachycardia, constipation, and rash.
Healthcare providers and/or their designee are responsible for mandatory FDA MedWatch reporting of all
6-K
EX-99.2
5da4 rcw4
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.3
vzigwrpyjmkjb5kz
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.1
z3dypcwe419 gq6yzs
4 Apr 24
Current report (foreign)
4:01pm
6-K
EX-99.1
t33 dx83mzh8v6g38k
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
EX-99.1
kgnpasuavd
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
EX-99.1
klniugrdj
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.1
2g3scrbop8ai39
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
wlruoo7uw8cdf
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
3sbg1aj8pg4hhr xmf4
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
EX-99.2
jc8ou
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.3
ie48ipkd
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.2
5csonkqnwrn
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
6wcpajyvuao25t snw8y
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-1.1
4m7heprsx7 nq8zs
13 Apr 23
Current report (foreign)
4:01pm